general transcription factor IIE subunit 2Genealiases: FE · TF2E2 · TFIIE-B · TTD6
Q-omics provides the consensus-scored GTF2E2 profile across patient tissues and cancer cell-line models. GTF2E2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GTF2E2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, GTF2E2 protein abundance shows 26,479 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where GTF2E2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2E2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2E2 survival associations across molecular data types. GTF2E2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2E2 RNA expression–survival associations across cancer types. High GTF2E2 expression shows unfavorable associations in MESO, KICH, KIRP, LIHC, ACC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GTF2E2 RNA expression.
This table summarizes GTF2E2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GTF2E2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2E2 shows higher tumor expression in HNSC, KIRP, KIRC, LUAD, COAD and LUSC. The HNSC box plot shows higher GTF2E2 RNA expression in tumor versus normal tissue (log2 FC = +1.123, t-test p < 0.001).
This table shows molecular features associated with GTF2E2 in patient tissues and cancer cell lines. In patient samples, GTF2E2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2E2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
